McNeil Products Ltd

Foundation Park, Roxborough Way, Maidenhead, Berks, SL6 3UG
Medical Information Direct Line: 01344 864042
Medical Information e-mail: medinfo@its.jnj.com
Summary of Product Characteristics last updated on the eMC: 07/12/2009
SPC Calpol Six Plus Suspension

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 07/12/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   23-Nov-2009
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Update to section 4.9 overdose section of SmPC

Updated on 15/10/2009 and displayed until 07/12/2009
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   05-Oct-2009
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Update to sections

4.1 of the SPC to include the indications of colds and influenza and to harmonise the other indications throughout the range.

4.8 of the SPC to add ‘anaphylactic reactions’ as a possible side-effect

Other updates to several sections of the SPC in line with current QRD template/regulatory guidelines and rephrasing of the storage conditions to some licences to align with the wording used across the current Calpol 6+ product range.

Updated on 07/05/2009 and displayed until 15/10/2009
Reasons for adding or updating:
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   04-Mar-2009
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Change – licence renewal. SPC updated to reflect this renewal date and date of revision.

 

Updated on 24/04/2008 and displayed until 07/05/2009
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   10/2007
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change to MA as a result of integration
Updated on 08/08/2007 and displayed until 24/04/2008
Reasons for adding or updating:
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   10/2005
Legal Category:   P
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 10: Change to date of revision of text
Updated on 28/09/2004 and displayed until 08/08/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 14/02/2004 and displayed until 28/09/2004
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 06/02/2004 and displayed until 14/02/2004
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 24/09/2002 and displayed until 06/02/2004
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
Updated on 24/08/2001 and displayed until 24/09/2002
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   paracetamol


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk